Wellington Management Group LLP Cuts Stock Holdings in Vanda Pharmaceuticals Inc. $VNDA

Wellington Management Group LLP trimmed its position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 23.8% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 265,888 shares of the biopharmaceutical company’s stock after selling 82,958 shares during the quarter. Wellington Management Group LLP owned approximately 0.45% of Vanda Pharmaceuticals worth $1,220,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in VNDA. Nuveen LLC purchased a new position in shares of Vanda Pharmaceuticals during the 1st quarter valued at approximately $2,022,000. Schonfeld Strategic Advisors LLC purchased a new stake in Vanda Pharmaceuticals in the 4th quarter worth $1,296,000. Millennium Management LLC increased its holdings in Vanda Pharmaceuticals by 67.4% in the 4th quarter. Millennium Management LLC now owns 668,693 shares of the biopharmaceutical company’s stock worth $3,203,000 after acquiring an additional 269,183 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in Vanda Pharmaceuticals by 10.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,488,519 shares of the biopharmaceutical company’s stock worth $11,920,000 after acquiring an additional 227,428 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Vanda Pharmaceuticals in the 1st quarter worth $875,000. 88.14% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently commented on VNDA. Cantor Fitzgerald reissued an “overweight” rating and issued a $13.00 price target on shares of Vanda Pharmaceuticals in a report on Wednesday, May 14th. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Vanda Pharmaceuticals in a report on Thursday, August 21st. Finally, Wall Street Zen lowered shares of Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Saturday, August 2nd. One analyst has rated the stock with a Strong Buy rating and one has assigned a Buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Strong Buy” and an average price target of $16.50.

Vanda Pharmaceuticals Stock Up 0.6%

Shares of NASDAQ VNDA opened at $4.73 on Monday. The firm has a 50-day simple moving average of $4.63 and a 200-day simple moving average of $4.53. The stock has a market capitalization of $279.50 million, a price-to-earnings ratio of -4.19 and a beta of 0.74. Vanda Pharmaceuticals Inc. has a 52 week low of $3.81 and a 52 week high of $5.55.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its earnings results on Thursday, July 31st. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.12). The business had revenue of $52.59 million during the quarter, compared to analyst estimates of $54.77 million. Vanda Pharmaceuticals had a negative net margin of 32.90% and a negative return on equity of 12.89%. Vanda Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current year.

Insider Activity at Vanda Pharmaceuticals

In other news, Director Stephen Ray Mitchell sold 7,000 shares of the stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $4.59, for a total value of $32,130.00. Following the completion of the sale, the director directly owned 97,082 shares in the company, valued at $445,606.38. This represents a 6.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 8.90% of the stock is owned by company insiders.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.